Protein / target
Synaptic vesicle glycoprotein 2A
Protein at a glance
Biological role
Transmembrane transporter activity
Primary system
Nervous system
Strongest disease association
Abnormality of the skeletal system
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
2 approved · 2 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles (By similarity)
Subcellular location
Domains and Gene Ontology detail (13)Hide
Gene Ontology
- Ccell-cell junction
- Cendoplasmic reticulum
- CGABA-ergic synapse
- Cglutamatergic synapse
- Cneuromuscular junction
- Cneuron projection
- Cplasma membrane
- Cpresynaptic active zone
- Csynaptic vesicle
- Csynaptic vesicle membrane
- Fprotein kinase binding
- Ftransmembrane transporter activity
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Synaptic signalling
- ·Presynapse
- ·GABA-ergic synapse
- ·glutamatergic synapse
- ·presynaptic active zone
Inhibitory neurotransmission
- ·GABA-ergic synapse
Excitatory neurotransmission
- ·glutamatergic synapse
Kinase signalling
- ·protein kinase binding
Cell adhesion
- ·cell-cell junction
View underlying pathways (4)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Synaptic vesicle glycoprotein 2A modulator
Appears in clinical studies involving Seizure, Bilateral tonic-clonic seizure, epilepsy, fibromyalgia
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 254 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 4 total
epilepsy · Seizure · Seizure
epilepsy
Seizure · Bilateral tonic-clonic seizure · epilepsy
Focal-onset seizure · epilepsy · epilepsy
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Regulatory approval
Approval: LEVETIRACETAM (ANDA215465)
- New publicationAntiepileptic Strategies for Patients with Primary and Metastatic Brain Tumors.
- New publicationEffect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial.
- New publicationAdjunctive levetiracetam in the treatment of Chinese and Japanese adults with generalized tonic-clonic seizures: A double-blind, randomized, placebo-controlled trial.
- Regulatory approval
Approval: Levetiracetam Hospira (EMA)
- New publication[Efficacy and safety of levetiracetam as adjunctive therapy in Japanese children with uncontrolled partial-onset seizures: multicenter and open-label study (N01223), short term evaluation].
- New publicationResults of phase II levetiracetam trial following acute head injury in children at risk for posttraumatic epilepsy.
- New publicationProspective Open-Label, Single-Arm, Multicenter, Safety, Tolerability, and Pharmacokinetic Studies of Intravenous Levetiracetam in Children With Epilepsy.
- New publicationResults of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy.
- New publicationResults of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy.
- Regulatory approval
Approval: Levetiracetam Sun (EMA)
- Regulatory approval
Approval: Levetiracetam Actavis Group (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.